Summary

The divalproex sodium market is projected to register a CAGR of 6.2% during the forecast period.

The COVID-19 pandemic has been continuing to transform the growth of various markets, the immediate impact of the outbreak is varied. While a few industries registered a drop in demand, numerous other markets may continue to remain unscathed and show promising growth opportunities. Initially, the outbreak of COVID-19 showed an impact on the divalproex sodium market by directly affecting its production, creating supply chain disruptions, and creating a financial impact on firms due to social distancing and lockdown measures taken by the government. However, demand for divalproex sodium is expected to rise at a considerable pace in the coming years.

Moreover, the major factors responsible for the growth of the divalproex sodium market include the growing incidence of bipolar disorders, rising patient pool with epilepsy and migraine headaches, and increasing government initiatives and rising research and development for the introduction of new products.

Increasing prevalence of bipolar disorders around the globe is propelling the divalproex sodium market growth. According to a study done by National Alliance on Mental Illness in 2017, the average age-of-onset of bipolar disorder is about 25, but it can occur in the teens, or more uncommonly, in childhood. The condition affects men and women equally, with about 2.8% of the U.S. population diagnosed with bipolar disorder and nearly 83% of cases classified as severe.

Moreover, rising patient pool around the world affected with epilepsy and migraine headaches is also expected to boost demand for divalproex sodium market significantly. For instance, according to the World Health Organization 2018 key facts, around 50 million people were globally affected with epilepsy, making it one of the most common neurological disease, and around 80% of the people with epilepsy live in low- and middle-income countries.

According to National Hospital Ambulatory Medical Care Survey, the National Ambulatory Medical Care Survey, and the National Health Interview Survey, In 2018, the age-adjusted prevalence of migraine was 15.9% across all adults in the United States. The sex ratio also remains stable, with 21% of women and 10.7% of men affected. Furthermore, increasing awareness regarding diseases and various government initiatives to prevent head migraine is expected to propel growth of divalproex sodium market size.

However, Stringent regulations and Increasing neurobehvaioral adverse effects, birth defects and suicidal tendency due to Divalproex Sodium usage are expected to restrain the divalproex sodium market growth.

Key Market Trends

Epilepsy and Migraine Headaches Segment is Expected to Account for the Largest Market Share During the Forecast Period

Epilepsy is one of the most common nervous system disorders which causes seizures. When there is an enduring predisposition of seizures it is called epilepsy. It can affect people of any age from children to adults of all races and backgrounds. For instance, seizures and epilepsy are some of the challenging health issues facing by many children. An epileptic seizure is said to be an abnormal electrical activity in your brain. It is a state of neurological activity that feels like a shock wave traveling through the brain and the recurrence of these repetitive unprovoked seizures is called epilepsy.

Migraine is a medical condition that involves severe, recurring headaches and other symptoms. Before the headache, there may be sensory changes that are known as an aura. As per a 2018 article, published by the American Academy of Family Physicians (AAFP), more than 15% of adults in the United States had experienced a migraine episode or a severe headache within 3 months. According to Migraine Research Foundation, 12% of the population, including children, suffers from migraines and around 18% of American women, 6% of men, and 10% of children experience migraines.

Rise in people getting affected by epilepsy and migraine headaches is projected to account for the largest market share during the forecast period. Epilepsy is triggered due to certain health conditions like brain tumors, strokes, brain infections, neurological defects, lack of oxygen to the brain, hyperpyrexia etc. Traumatic head and brain injuries, specific genetic conditions, smoking and drinking alcohol also lead to epilepsy. Whereas, migraine is triggered due to hormonal changes, emotional triggers such as stress, depression anxiety, Dietary factors like alcohol, caffeine, medications, and environmental factors.

In the present scenario, living styles of people has induced anxiety and stress in their daily life due to which patient pool getting affected by epilepsy and migraine headaches is expected to increase during the forecast period and contribute as a driving factor for divalproex sodium market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

In North America, the United States divalproex sodium market, holds the major shared. Owing to increased government initiatives and rising research and development for the introduction of new products are expected to aid in the growth of the divalproex sodium market in the region. According to Centers for Disease Control and Prevention, approximately 3 million adults and 470,000 children in the United States have epilepsy. According to a survey of 11 countries performed by Therapeutic Advances in Psychopharmacology, 2018, the lifetime prevalence of bipolar disorder was 2.4% and out of that 1% of prevalence was found in the United States, which is higher than other countries in the survey.

Furthermore, In 2019 Lupin received the approval for divalproex sodium extended-release tablets USP 250 mg and 500 mg from US FDA, for commercializing generic equivalent of depakote extended release Tablets, 250 mg, and 500 mg, of AbbVie. These advancements are expected to drive the market growth over the forecast period.

Competitive Landscape

The divalproex sodium market is consolidated and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are AbbVie Inc., Zydus Cadila, Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Lupin Pharmaceuticals, Inc., Orchid Pharma Ltd., Sun Pharmaceuticals Industries Ltd., Teva Pharmaceutical Industries Ltd., Abbott Laboratories etc.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

ページTOPに戻る

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Incidence of Bipolar Disorders
4.2.2 Rising Patient Pool with Epilepsy and Migraine Headaches
4.2.3 Increasing Government Initiatives and Rising Research & Development for the Introduction of New Products
4.3 Market Restraints
4.3.1 Stringent Regulations
4.3.2 Increasing Neurobehvaioral adverse effects, birth defects and suicidal tendency due to Divalproex Sodium Usage
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Tablet
5.1.2 Capsule
5.1.3 Syrup
5.2 By Application
5.2.1 Epilepsy and Migraine Headaches
5.2.2 Manic-Depressive Illness
5.2.3 Others
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Zydus Cadila
6.1.3 Aurobindo Pharma
6.1.4 Dr. Reddy's Laboratories Ltd.
6.1.5 Lupin Pharmaceuticals, Inc.
6.1.6 Orchid Pharma Ltd.
6.1.7 Sun Pharmaceuticals Industries Ltd.
6.1.8 Teva Pharmaceuticals Industries Ltd.
6.1.9 Abbott Laboratories

7 MARKET OPPORTUNITIES AND FUTURE TRENDS